Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STS-01 for alopecia areata
ISRCTN14007390Phase 2Completed
- Sponsor
- Soterios Pharma
- Start
- Mar 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised trial of STS-01 in alopecia areata (5 arms), sponsored by Soterios Pharma. Primary endpoint: Alopecia areata severity by SALT at 8 months. Started Mar 2022; status: completed.
02
Drugs
STS-01
03
Conditions
alopecia areata
Beyond the preview
Go deeper on ISRCTN14007390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14007390.